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Abstract  1 
Docetaxel (DTX)-loaded liposomes have been formulated to overcome DTX solubility issue, 2 
improve its efficacy and reduce its toxicity. This study investigated the effect of steric 3 
stabilisation, varying liposome composition, and lipid:drug molar ratio on drug loading and on 4 
the physicochemical properties of the DTX-loaded liposomes. Size exclusion chromatography 5 
(SEC) was used to remove free DTX from the liposomal formulation, and its impact on drug 6 
loading and in vitro cytotoxicity was also evaluated.  Liposomes composed of fluid, unsaturated 7 
lipid (DOPC:Chol:DSPE-PEG2000) showed the highest DTX loading compared to rigid, saturated 8 
lipids (DPPC:Chol:DSPE-PEG2000 and DSPC:Chol:DSPE-PEG2000). The inclusion of PEG showed a 9 
minimum effect on DTX encapsulation. Decreasing lipid:drug molar ratio from 40:1 to 5:1 led 10 
to an improvement in the loading capacities of DOPC-based liposomes only.  Up to 3.6-fold 11 
decrease in drug loading was observed after liposome purification, likely due to the loss of 12 
adsorbed and loosely entrapped DTX in the SEC column. Our in vitro toxicity results in PC3 13 
monolayer showed that non-purified, DTX-loaded DOPC:Chol liposomes were initially (24 h) 14 
more potent than the purified ones, due to the fast action of the surface- adsorbed drug. 15 
However, we hypothesize that over time (48 and 72 h) the purified, DTX-loaded DOPC:Chol 16 
liposomes became more toxic due to high intracellular release of encapsulated DTX. Finally, 17 
our cytotoxicity results in PC3 spheroids showed the superior activity of DTX-loaded liposomes 18 
compared to free DTX, which could overcome the DTX poor tissue penetration, drug 19 
resistance, and improve its therapeutic efficacy following systemic administration.  20 
 21 
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1. Introduction 1 
Taxanes are a key class of anticancer agents that are clinically used to treat a wide range of 2 
conditions,  including breast and  prostate  cancers (Gelmon, 1994). They inhibit cell 3 
proliferation by inducing a sustained mitotic blockage at the metaphase/anaphase stage of the 4 
cell cycle, promoting polymerization of stable microtubules and preventing their disassembly 5 
(Horwitz, 1992; Lavelle et al., 1995). However, as shown by clinical trials, paclitaxel and 6 
docetaxel (DTX), predispose patients to toxicities such as neutropenia, peripheral neuropathy 7 
and hypersensitivity reactions, narrowing their therapeutic window (Rowinsky, 1997; Weiss et 8 
al., 1990). DTX, a member of the taxanes family, has been particularly promising as a 9 
therapeutic agent (Friedenberg et al., 2003) and is preferable to paclitaxel (PTX) due to its 10 
enhanced solubility in water and increased potency (Grant et al., 2003). Taxotere® is the 11 
commercially available formulation of DTX. Currently, the presence of Tween 80® (polysorbate 12 
80) and ethanol (50:50, v/v) in Taxotere® formulation  has been associated with serious 13 
hypersensitivity reactions in patients (Tan et al., 2012). 14 
Encapsulation of anti-cancer drugs in nanoformulations, such as liposomes, can decrease drug 15 
clearance and reduce its associated toxicity (Crosasso et al., 2000). Liposomes are the most-16 
clinically developed delivery systems. They are biodegradable, biocompatible and have the 17 
ability to encapsulate both hydrophilic and lipophilic drugs (Zhang et al., 2012).  A phase I 18 
clinical trial was carried out with liposomal docetaxel for advanced solid tumour, and showed 19 
good tolerance profile and clinical benefits. As an outcome, a phase II trial has been planned 20 
with a dose of 85 mg/m2 triweekly (Deeken et al., 2013). In the past few years, several efforts 21 
have been made to develop a successful nanocarrier for DTX. Muthu M. et al. engineered D-22 
alpha-tocopheryl PEG1000 succinate mono-ester (TPGS) coated liposomes for the delivery of 23 
DTX and quantum dot nanoparticles. These liposomes were prepared by the solvent injection 24 
method and presented DTX encapsulation efficiency up to 54 %, higher than those obtained 25 
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with PEG-coated and conventional liposomes. Cellular uptake studies in C6 glioma brain cancer 1 
cells further revealed superior uptake of these liposomes compared to those obtained with 2 
PEG-coated and conventional liposomes (Muthu et al., 2012). In another study, Li X. et al. 3 
developed folate-poly (PEG-cyanoacrylate-co-cholesteryl cyanoacrylate) (FA-PEG-PCHL)-4 
modified freeze-dried liposomes for targeted DTX chemotherapy, which displayed sustained 5 
release profile, promoted cell toxicity and apoptosis and enhanced the bioavailability at the 6 
tumour site (Li et al., 2011). In an attempt to target transferrin receptor (TfR) in cancer cells, 7 
Zhai et al. prepared DTX-loaded liposomes composed of hydrogenated soy 8 
phosphatidylcholine (HSPC)/ egg phosphatidylcholine (PC)/ cholesterol (Chol)/ mPEG2000-DSPE 9 
by a post-insertion method. TfR-targeted liposomes loading DTX induced higher toxicity than 10 
the non-targeted liposomes in KB cells (Zhai et al., 2010). 11 
Drug content, liposome size, liposome stability and blood circulation are key parameters that 12 
should be taken into account while developing liposome-based formulations (Senior and 13 
Gregoriadis, 1982). High drug loading is always desirable to accelerate the clinical translation 14 
of liposomal formulations, since high lipid concentrations may raise concerns of toxicity and 15 
reduce the viability of large-scale production (Straubinger and Balasubramanian, 2005). The 16 
present study focuses on investigating the effect of lipid composition, steric stabilisation 17 
(known as pegyaltion) and varying DTX to lipid ratio on DTX encapsulation into liposomes. The 18 
effect of purification using size exclusion chromatography (SEC) was also evaluated and the in 19 
vitro toxicity of non-purified and purified DTX-loaded liposomes was assessed in prostate 20 
cancer cell lines. In addition, prostate cancer (PC3) spheroids were used to demonstrate the 21 
enhanced toxicity of DTX-loaded liposomes in multicellular tumour spheroids. 22 
 23 
2. Materials and Methods 24 
2.1 Materials 25 
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1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-1 
phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 2 
 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] 3 
(DSPE-PEG2000) were a  generous gift  from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol 4 
(Chol), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES, ≥ 99.5 %), sodium chloride 5 
(≥ 99.0 %) and resazurin reagent (R7017) were purchased from Sigma-Aldrich (UK). Chloroform 6 
(HPLC grade), acetonitrile (HPLC grade), methanol (HPLC grade), ethanol (absolute 99.8 %) and 7 
sterile 0.2 µm pore size syringe filters were all obtained from Thermo Fisher Scientific (UK). 8 
Advanced Roswell Park Memorial Institute (RPMI) 1640 with 2 g/L D-glucose, 110 mg/L sodium 9 
pyruvate and non-essential amino acids, GlutaMAX™ supplement 200 mM, penicillin-10 
streptomycin Solution liquid (10000 units/ml), 0.05 % Trypsin/EDTA, Trypan Blue Stain (0.4 %, 11 
1:1 v/v) and Dulbecco’s PBS (1X) were purchased from Invitrogen Gibco® Life Technologies 12 
(UK). Heat inactivated newborn fetal bovine serum (FBS) was obtained from First Link (UK). 13 
Docetaxel (DTX) was supplied by NCE Biomedical Co., Ltd (China).  14 
2.2 Preparation of DTX-loaded liposomes 15 
Liposomes were prepared by thin film hydration method as previously described (Al-Jamal et 16 
al., 2008). Briefly, stock solution of lipids, DTX and solvent, chloroform: methanol (4:1, v/v), 17 
were added to a 25 mL round bottom flask (Thermo Fisher Scientific UK). The lipids had a fixed 18 
concentration of 5 mM, while DTX concentration was varied to reflect the desired 19 
phospholipid to drug molar ratio. Liposomes were prepared at different lipid: DTX molar ratios 20 
(40:1, 20:1, 10:1 and 5:1). DOPC:Chol:DSPE-PEG2000, DPPC:Chol:DSPE-PEG2000 and 21 
DSPC:Chol:DSPE-PEG2000 were prepared  at  molar ratio of 95:50:5, while DOPC:Chol liposomes 22 
were prepared at a molar ratio of 100:50. Total phospholipid: cholesterol molar ratio was kept 23 
at 2:1. The organic solvents were then removed under rotary evaporation at T > Tc i.e. 60 °C for 24 
DOPC and DPPC and 65 °C for DSPC, at around 144 rpm which led to the formation a thin lipid 25 
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film. The film was hydrated for 30 min with 1 mL of 0.2 µm filtered HEPES Buffer Saline (HBS) 1 
at 60 °C for DOPC and DPPC, and at 65 °C for DSPC formulation. In order to obtain small 2 
unilamellar vesicles (SUVs) from the hydrated lipids, extrusion technique was used. Extrusion 3 
was carried out at 60 °C for DOPC and DPPC liposomes and at 65 °C for DSPC liposomes. 4 
Briefly, the hydrated mixture was passed through a series of polycarbonate membranes of 5 
decreasing pore size (0.8 µm, 5 cycles; 0.2 µm, 15 cycles; 0.1 µm, 11 cycles) using a mini-6 
extrusion device (Avanti Polar Lipids Inc, AL, USA). Samples were collected before the extrusion 7 
process in order to determine DTX encapsulation efficiency (EE) and the lipid loss. Liposomes 8 
were flushed with N2 stream and stored at at 4 °C. The next day, liposomes were purified by 9 
SEC using PD-10 columns packed with Sephadex™ G-25 medium (GE Healthcare Life Sciences, 10 
UK).  Following SEC, samples were left at least 2 h at RT before further characterization. 11 
2.3 Physicochemical characterisation of DTX-loaded liposomes 12 
Measurement of the hydrodynamic diameter and zeta potential (ZP) of the prepared 13 
formulations were performed using dynamic light scattering (DLS) with a Malvern Zetasizer 14 
Nano ZS (Malvern, UK; He-Ne laser). Disposable polystyrene cells and disposable plain folded 15 
capillary Zeta cells (Malvern, UK) were used. Suspensions were diluted in 0.2 µm filtered 16 
deionized water at ratios of 1:100 for size measurements and 1:10 for ZP measurements. All 17 
measurements were performed at 25 °C. Electrophoretic mobility was used to calculate the ZP 18 
using the Helmholtz-Smoluchowski equation. The hydrodynamic size was presented as the 19 
average value of 20 runs with triplicate measurements within each run, while ZP 20 
measurements were performed in quintuplicate. 21 
2.4 Determination of DTX encapsulation efficiency and loading content 22 
DTX was quantified either by high performance liquid chromatography (HPLC) or by UV-Vis 23 
spectrophotometry in order to evaluate which method was more sensitive and accurate. 24 
2.4.1 HPLC 25 
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Briefly, 50 µL of DTX-loaded liposomes before extrusion, before purification and after 1 
purification were diluted 1:10 (v/v) in acetonitrile sonicated for 10 min to ensure complete 2 
liposome disruption. 20 µL were injected in an analytical HPLC column (Eclipse XDB-C18 4.6x150 3 
mm, 5 µm, Agilent UK) and 15 min runs were performed in a mobile phase composed of water: 4 
acetonitrile (50:50, v/v). The flow rate was set at 1.0 mL/min and DTX was detected at λ= 230 nm. 5 
The calibration curve was linear in the range of 0.05-400 µg/mL with a correlation coefficient of R2= 6 
0.997. DTX encapsulation efficiency (EE) and drug loading were calculated using equations (1) EE= 7 
µg of encapsulated drug/ µg of total drug x 100 and (2) Drug loading= µg of drug/ mg of total lipid. 8 
Measurements were performed in triplicate and results were presented as mean ± SD. 9 
2.4.2 UV-Vis spectrophotometry 10 
Samples of DTX liposomes before extrusion and after extrusion (before purification) were 11 
withdrawn and made up with ethanol, maintaining a fixed concentration of 20 µg/mL. Ethanol 12 
was used to disrupt the liposomes and release DTX. A lambda 35 UV-Vis spectrophotometer 13 
(Perkin Elmer Lambda, USA) was used to determine the absorbance of DTX at λ= 230 nm. The 14 
calibration curve was linear in the range of 0-45 μg/mL with a correlation coefficient of R2= 15 
0.995. The obtained DTX concentrations were then used to determine DTX encapsulation 16 
efficiency before purification. 17 
2.5 Phospholipid quantification by Stewart assay 18 
Phospholipid content was determined in samples before extrusion, before purification and 19 
after purification according to the previous protocol established by Stewart (Stewart, 1980). 20 
Briefly, 2 mL of chloroform were transferred to 15 mL test tubes (Thermo Fisher Scientific, UK) 21 
and 20 μL of liposome samples were added to the organic solvent. Finally, 2 mL of 0.1 M 22 
ammonium ferrothiocyanate were transferred to the same tube and the components were 23 
vortexed vigorously for 15 s. For phase separation, the mixture was centrifuged at 1000 x g, 10 24 
min and the organic phase recovered by careful pipetting. The lipid absorption was then 25 
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measured using a Lambda 35 spectrophotometer (Perkin Elmer, USA) at 465 nm. Phospholipid 1 
content was determined using a calibration curve performed with empty liposomes. Triplicate 2 
samples were prepared for all measurements and blanks were used for baseline reference. 3 
The results were expressed as mean ± SD. 4 
2.6 PC3 culture and maintenance 5 
Androgen-independent PC3 cells (CRL-1435™) were purchased from American Type Culture 6 
Collection (ATCC®, USA). PC3 cells were cultured in Advanced RPMI 1640 supplemented with 7 
10 % FBS, 50 U/mL penicillin, 50 μg/mL streptomycin and 1 % L-glutamine and maintained in a 8 
humidified chamber (BB15 CO2 incubator, Thermo Fisher Scientific, UK) at 37 °C in 5 % CO2. 9 
Cells were routinely grown in 75 cm2 canted-neck tissue culture flasks and passaged twice a 10 
week using 0.05 % Trypsin/ EDTA when reaching 80 % confluence in order to maintain 11 
exponential growth. 12 
 13 
2.7 Cytotoxicity of DTX-loaded liposomes in prostate cancer (PC3) monolayers 14 
PC3 cells were trypsinized, stained with Trypan Blue (0.4 %, 1:1 v/v ratio) and counted using a 15 
hemocytometer. Cells were seeded at a seeding density of 1 x 104 cells/well in polysterene 96-16 
well plates (Nunclon, Thermo Fisher Scientific, UK) in complete RPMI 1640 media. Next day, 17 
non-purified or purified DOPC:Chol or DOPC:Chol:DSPE-PEG2000 liposomes (prepared at 20:1 18 
lipid:DTX molar ratio) containing 1-1000 nM of DTX were diluted in serum-free and antibiotics-19 
free media and added to the cells. Untreated cells were used as a 100 % viability control. After 20 
4 h incubation, media containing liposomes were removed, cells were washed with PBS and 21 
replenish with fresh media supplements with 10 % (v/v) FBS and 1 % (v/v) antibiotics. At 24, 48 22 
and 72 h post-incubation, a resazurin cell viability assay was performed, which is based on the 23 
mitochondrial metabolic activity of live cells. Resazurin reagent was prepared as described by 24 
Walzl et al. (Walzl et al., 2014). Briefly, cells were incubated with 0.01 mg/mL resazurin 25 
9 
 
solution for 4 h. After incubation, fluorescence (λex = 544 nm, λem = 590 nm) was read using an 1 
automated FLUOstar Omega (BMG Labtech, UK) plate reader. Six replicates per condition were 2 
used. The results were expressed as the percentage of cell viability (mean ± SEM) and 3 
normalized to control untreated cells. 4 
2.8 Cytotoxicity of DTX-loaded in PC3 multicellular tumour spheroids   5 
PC3 multicellular tumour spheroid formation and growth were aided by coating polystyrene 6 
96-well plates with 100 μL of 1 % (w/v) agarose in order to provide a non-adherent concave 7 
surface. PC3 cells were suspended using 0.05 % Trypsin/ EDTA and 5 x 103 cells/well were 8 
seeded onto the pre-coated plates in 200 μL of complete RPMI 1640 media. Spheroid growth 9 
was monitored daily and 50 % of media was replenished every 3 days. PC3 spheroids were 10 
grown for 7 days until they reached ~ 0.7 mm in diameter before use. For cytotoxicity 11 
assessment, spheroids were incubated with DOPC (± PEG) liposomes containing 1-10000 nM of 12 
DTX. For comparison purposes, spheroids were also incubated with 0.1-1000 nM of free DTX. 13 
Following treatment, free DTX toxicity and DTX-loaded liposomes toxicity were assessed at 48, 14 
72 and 96 h by resazurin assay. Briefly, 100 μL of media was removed from each well and 15 
spheroids were incubated with 0.01 mg/mL resazurin solution for 4 h. After incubation, 16 
fluorescence (λex = 544 nm, λem = 590 nm) was read using an automated FLUOstar Omega 17 
(BMG Labtech, UK) plate reader. Six replicates per condition were used. The results were 18 
expressed as the percentage of cell viability (mean ± SEM) and normalized to control untreated 19 
spheroids. 20 
2.9 Statistical analysis 21 
Statistical analysis was performed using a two-way analysis of variance (ANOVA). In all cases, 22 
post hoc comparisons of the means of individual groups were performed using Bonferroni´s 23 
test. A significance level of p< 0.05 denoted significance in all cases. Statistical analysis was 24 
performed using GraphPad Prism® version 6.0h (GraphPad Software Inc., CA, USA). 25 
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 1 
3. Results 2 
3.1. Preparation and characterisation of DTX-loaded liposomes 3 
In the present study, DTX-loaded, DOPC:Chol, DOPC:Chol:DSPE-PEG2000, DPPC:Chol:DSPE-4 
PEG2000 and DSPC:Chol:DSPE-PEG2000 liposomes were prepared using lipid film hydration and 5 
extrusion method. Liposomes were prepared at different lipid:DTX molar ratios (40:1, 20:1, 6 
10:1 and 5:1) and purified using size exclusion chromatography (SEC). Cholesterol was included 7 
in all formulations at 50 mol % to stabilise the bilayer structure and improve liposome stability 8 
in serum (Drummond et al., 2008; Kirby and Gregoriadis, 1980).  5 mol % DSPE-PEG2000 was 9 
incorporated in the formulation to sterically stabilise the liposomes and prolong their blood 10 
circulation in vivo (Lokerse et al., 2016).  11 
Table 1 12 
Table 1 represents the physicochemical properties (the size and the surface charge) of DTX-13 
loaded, DOPC:Chol liposomes (100:50 molar ratio). Liposomes were formed at all different 14 
lipid:DTX ratios used. Interestingly, DTX-loaded liposomes, were smaller than the empty 15 
liposomes. Moreover, lowering lipid:DTX molar ratios consistently showed liposomes with 16 
smaller size and lower polydispersity index (PdI). The same trend was maintained following 17 
SEC purification step (Table 1). However, the purified liposomes exhibited slightly smaller size 18 
and lower PdI, which could be explained by the removal of unencapsulated DTX aggregates. No 19 
difference was observed in the zeta potential of all purified samples (Table 1), which was 20 
expected due to the incorporation of DTX into the lipid bilayer. 21 
Table 2 22 
Next, we evaluated the incorporation of DTX into sterically stabilised liposome formulations. 23 
Liposome fluidity was maintained by using DOPC:Chol:DSPE-PEG2000 formulation. PEGylated 24 
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liposomes were smaller in size (ranging from 112-126 nm) compared to non-PEGylated DOPC 1 
liposomes (ranging from 129-162 nm), across all lipid:DTX ratios (Table 2). The incorporation of 2 
DSPE-PEG2000 was confirmed by a slight increase in the negative charge of liposomes (increased 3 
from -5 mV to -9 mV) (Table 1 and 2). This could be explained by the presence of the 4 
carbamate linker that is used to couple PEG2000 chain to DSPE, resulting in a net negative 5 
charge on the phosphate moiety at physiological pH (Webb et al., 1998). Similar to previous 6 
results, a reduction in liposome size was observed by decreasing lipid:DTX molar ratios. 7 
Table 3 8 
PEGylated liposomes with higher phase transition, such as DPPC and DSPC exhibited similar 9 
patterns to DOPC:Chol:DSPE-PEG2000, where smallest liposomes were obtained at low lipid:DTX 10 
molar ratio (5:1) (Table 3 and 4). Interestingly, purified DPPC:Chol:DSPE-PEG2000 and 11 
DSPC:Chol:DSPE-PEG2000 liposomes displayed lower PdI values across all the lipid:drug ratios 12 
tested in comparison to DOPC-based liposomes (Table 2). Such observation suggests that 13 
incorporation of DPPC and DSPC as the main lipid in the formulation resulted in narrowly-14 
dispersed nanoparticles with no aggregation in water. Moreover, liposome size did not 15 
significantly change after purification as big drug aggregates, observed with DSPC and DPPC at 16 
10:1 and 5:1 molar ratios, were lost during the extrusion step. All formulations were stable in 17 
size up to one-month storage at 4°C (Table A.1-A.4). 18 
Table 4 19 
3.2. The effect of size exclusion chromatography on DTX encapsulation into liposomes  20 
Following characterising DTX-liposomes for size and surface charge, the encapsulation 21 
efficiencies (EE) of DTX into liposomes with different lipid compositions were determined using 22 
HPLC. Unsaturated lipid (DOPC:Chol) and PEGylated, unsaturated DOPC:Chol:DSPE-PEG2000, 23 
and saturated DPPC:Chol:DSPE-PEG2000 and DSPC:Chol:DSPE-PEG2000 liposomes were prepared 24 
at different lipid:DTX molar ratios (40:1, 20:1 ,10:2, 5:1) using lipid film hydration and extrusion 25 
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method. Figure 1a depicts the EE of DTX into liposomes, which was calculated as a ratio 1 
between the amount of drug encapsulated and the initial amount used. Non-PEGylated, 2 
unsaturated DOPC:Chol liposomes showed the highest EE between all formulations (around 3 
90%)  up to 10:1 lipid:DTX molar ratio, then dropped to 46.1 % at 5:1 molar ratio. Incorporating 4 
5 mol % DSPE-PEG2000  into DOPC:Chol liposomes affected the EE of DTX at lipid:DTX molar 5 
ratio of 10:1. The highest EE (> 95 %) was still observed at 40:1 lipid:DTX molar ratio, and the 6 
lowest percentage (< 40 %) at 5:1 ratio. This result highlights the effect of PEG2000 on the EE of 7 
some drugs, which should be taken into account while designing sterically stabilised, long 8 
circulating liposomes for in vivo applications.  9 
Strikingly, when saturated lipids (DPPC and DSPC) were used, lower EE were achieved. Highest 10 
EE (< 55 %) was obtained at high lipid:DTX molar ratio (40:1) with both formulations. 11 
Decreasing lipid:DTX molar ratio to 5:1 resulted in a significant reduction in the EE (< 10 %). In 12 
general, DSPC:Chol:DSPE-PEG2000 liposomes encapsulated higher amount of DTX than DPPC-13 
based formulation (Figure 1a). As mentioned previously, large precipitates were observed 14 
immediately after hydrating DPPC and DSPC formulations with high DTX contents (10:1 and 5:1 15 
lipid: DTX molar ratios), which resulted in high DTX loss on the membrane filters during 16 
extrusion. Similar profile of EE was observed using UV-Vis spectrophotometry, however, 17 
overestimation of EE was observed with DOPC-based formulations. Most probably due to lipid 18 
interference at the applied wavelength (data not shown). This confirms that HPLC is more 19 
accurate technique to quantify the EE of DTX into liposomes, particularly following the 20 
purification step. 21 
Figure 1 22 
 23 
Following liposome purification using SEC, a significant reduction in EE was observed with all 24 
liposome formulations (data not shown). The EE could not be measured in DPPC and DSPC 25 
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formulations as the amounts of the encapsulated DTX were below the detection limit of the 1 
machine (0.50 ng/mL). To check if the drastic reduction in EE after purification was due to 2 
liposome loss during SEC, a Stewart assay was carried out to quantify the phospholipids 3 
recovery after extrusion (before purification) and purification processes (Table A.5). All 4 
formulations showed lipid recoveries following SEC, ranging between 90-100 %. These results 5 
show that the lipid loss during SEC did not account for such a significant amount of drug that 6 
was lost during purification. We believe that if the drug was not fully embedded in the bilayer 7 
but was rather associated with the outer surface of the liposomes, it could be lost during the 8 
purification process, leading to a reduction in the EE without an accompanying decrease in the 9 
lipid content. 10 
Figures 1b depicts the drug loading of DTX into liposomes, where the results were expressed as 11 
mol% of DTX/total lipid. It is important to highlight the different profiles obtained between EE 12 
and drug loading. Prior purification, DOPC:Chol liposomes showed rather similar drug EE across 13 
40:1, 20:1 and 10:1 lipid:drug ratios and a marked reduction at 5:1 ratio  (Figure 1a). However, 14 
this trend was not observed with drug loading, where the amount of DTX loaded into the 15 
liposomes increased with the decrease in the lipid:drug ratio (increased from 2.5 mol% 16 
DTX/total lipid to 9.7 mol% DTX/total lipid, at 40:1 and 5:1 ratios, respectively, Figure 1b). 17 
Same trend was observed with PEGylated DOPC:Chol:DSPE-PEG2000 formulation, where the 18 
profile of the drug loading was inversely proportional to the EE. Thus, drug loading increased 19 
as lipid:drug ratio lowered, reaching a maximum of 9.7  0.11 mol% DTX/total lipid at 5:1 ratio. 20 
When saturated DPPC lipid was used as the main lipid, drug loading ability of the nanocarrier 21 
was extremely poor independently of the initial amount of drug. Similarly, DSPC liposomes 22 
displayed drug loadings in the range of DPPC liposomes, although the highest lipid:drug ratios 23 
(40:1 and 20:1) were superior compared to 10:1 and 5:1 ratios. These results were in 24 
agreement with data obtained for DSPC EE before purification (Figure 1a). Following SEC 25 
purification, 1.6- and 3.6-fold decrease in drug loading was observed with both DOPC-based 26 
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liposomes (Figure 1c), in line with the results obtained for the EE (data not shown). Due to the 1 
reduced loading capacity of DPPC and DSPC liposomes and because of the high drug lost during 2 
purification process, it was not possible to assess the drug loading for these formulation 3 
(Figure 1c). Overall, these results emphasise the importance of expressing the data as drug 4 
loading as well as EE, as in some cases expressing the results as EE could be misleading. For 5 
instance, DOPC-based formulations (conventional or stealth liposomes), although the highest 6 
EE were obtained for the lower lipid:drug ratios, liposomes prepared at 5:1 ratios encapsulated 7 
the highest amount of DTX, despite the high drug loss during extrusion and purification steps.  8 
3.3. The effect of purification on the toxicity of DTX-loaded liposomes in vitro  9 
In the previous section, the effect of SEC purification on DTX loading into liposomes was 10 
investigated. In this experiment, we studied the effect of purification on the toxicity of DTX-11 
loaded liposomes in vitro. DTX-loaded liposomes were prepared by incorporating DTX into 12 
DOPC:Chol and DOPC:Chol:DSPE-PEG2000 liposomes at 20:1 lipid:DTX molar ratio. Other 13 
Liposomal formulations were not tested due to the poor encapsulation efficiency of DTX. 14 
Prostate cancer (PC3) cells were incubated with the same concentration of DTX, which was 15 
ranging between 1-1000 nM, as determined by the HPLC. Cells were incubated with non-16 
purified, and purified DTX-loaded liposomes (DOPC:Chol and DOPC:Chol:DSPE-PEG2000)  for 4 h 17 
in serum-free media, then cells were washed and incubated with fresh serum-containing 18 
media for 24, 48 or 72 h. Cell viability was determined using the resazurin cell viability assay. 19 
Figure 2 depicts the dose-response curves and the relative IC50 (defined as the half maximal 20 
inhibitory concentration) and % Imax (defined as the maximum inhibition, here the lowest cell 21 
viability achieved) of DTX-loaded DOPC:Chol and DOPC:Chol:DSPE-PEG2000 liposomes  at the 22 
different time points. As it can be seen in Figure 2a, at 24 h, DTX-loaded, DOPC:Chol liposomes 23 
had comparable potencies before and after purification (IC50 = 3.1 ± 0.5 nM vs. 2.3 ± 0.9 nM, 24 
respectively). However, the non-purified DOPC:Chol liposomes led to a significant higher cell 25 
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death at DTX concentrations between 10-1000 nM (% Imax= 42.2 ± 0.7) compared to purified 1 
liposomes (% Imax = 54.8 ± 1) (Figure 2a). This observation could be explained by the rapid 2 
onset of loosely-attached DTX to the liposome surface, thus exhibiting a “free drug-like 3 
behavior”. DTX that was not fully embedded in the lipid bilayer would have a faster onset of 4 
action compared to the DTX that was fully encapsulated in the liposomes (i.e. purified 5 
samples), which encountered an extra barrier of liposome release before exerting its 6 
cytotoxicity.  However, at 48 h the incubation time was long enough to allow the encapsulated 7 
DTX to be released intracellularly from DOPC:Chol liposomes, leading to a higher cytotoxicity 8 
compared to 24 h time point. At 48 h, the purified DTX-loaded DOPC:Chol liposomes were 9 
more potent than the non-purified ones (IC50 = 1.6 ± 0.1 nM vs. 5.2 ± 0.5 nM, respectively) 10 
(Figure 2b), which could be explained by the higher stability of DTX fully-encapsulated into 11 
liposomes, compared to loosely-associated DTX with the outer surface of the liposomes. 12 
Similarly, 72 h post incubation, purified DOPC:Chol liposomes were significantly more potent 13 
than non-purified DOPC:Chol liposomes (IC50= 2.1 ± 0.1 nM vs. IC50= 3.7 ± 0.1 nM, respectively) 14 
(Figure 2c). On contrary to non-PEGylated liposomes DOPC:Chol, DOPC:Chol:DSPE-PEG2000 15 
showed no statistically significant toxicity profile between non-purified and purified liposomes, 16 
presumably due to the steric effect of PEG chains, which may delay internalization of DTX-17 
loaded liposomes into cells. It is worth noting that at concentrations between 1-5 nM, 18 
PEGylated liposomes were less cytotoxic compared to the non-PEGylated equivalents, 19 
however, at higher concentrations the toxicity of PEGylated liposomes was similar to that 20 
achieved with non-PEGylated DOPC:Chol liposomes. 21 
Figure 2 22 
3.4 Toxicity of DTX-loaded liposomes in prostate cancer tumour spheroids 23 
In order to assess the cytotoxicity of DTX-loaded liposomes in tumour spheroids, DTX-loaded, 24 
DOPC:Chol liposomes (conventional or stealth) were prepared at 20:1 lipid:drug molar ratio, 25 
16 
 
purified using SEC,  then incubated in complete media  with PC3 prostate cancer spheroids for 1 
48, 72 and 96 h. Spheroids were incubated with free DTX for comparison. 2 
Overall, PC3 spheroids were more resistant to DTX treatment compared to PC3 monolayers. 3 
Prostate cancer spheroids incubated with free DTX did not show any dose-dependent or time-4 
dependent toxicity profiles (Figure 3a). No significant difference in cytotoxicity viability was 5 
observed in cells incubated with DTX concentrations ranging between 1-10000 nM, where cell 6 
viability ranged between 50-60%.  Moreover, cell death did not increase with prolonged 7 
exposure times (24-72 h). Shorter (24 h) and longer (96 h) DTX exposure times did not enhance 8 
the toxicity of free DTX (data not shown). This could be justified by the fast action of free DTX, 9 
combined with its poor penetration through the inner cell layers of the spheroids, which could 10 
explain the limited efficacy of DTX in vivo. In contrast to free DTX, both conventional (non-11 
PEGylated) and PEGylated DTX-loaded liposomes exhibited dose- and time-dependent toxicity 12 
profiles. DTX-loaded liposomes showed lower cell death after 48 h incubation, compared to 13 
free DTX (Figure 3b & 2c, respectively). Similar observations were obtained in monolayers 14 
(data not shown). However, high cell death was observed with DTX-loaded liposomes at the 15 
concentrations of 100 and 1000 nM, at longer incubation time (72 and 96 h). This 16 
demonstrated the enhanced cell killing of DTX-liposomal formulations compared to the free 17 
DTX, under same conditions. These results could suggest the higher stability of DTX upon 18 
encapsulation into nanocarriers, as well as the enhanced permeability and diffusion of 19 
liposomes in the tumour tissue. Overall, PEGylated, DTX-loaded liposomes were less toxic to 20 
PC3 tumour spheroids, compared to non-PEGylated DTX-loaded liposomes, after 48 and 72 h. 21 
However, after 96 h incubation, PEGylated DTX-loaded liposomes at high concentrations (100, 22 
1000 nM) induced reduction in the cell viability that was comparable with that achieved with 23 
conventional DTX-loaded liposomes. These findings highlight the potential use of liposomes to 24 
enhance the therapeutic efficacy of DTX in vivo by enhancing the drug accumulation and 25 
penetration in tumour tissues.  26 
17 
 
 1 
 2 
Figure 3 3 
4. Discussion 4 
Liposomes are the most clinically developed nanosystems to deliver cytotoxic drugs. DTX-5 
loaded liposomes have been formulated to overcome DTX solubility issue, improve its efficacy 6 
and reduce its toxicity. However, in order for liposomes to be classed as an effective DTX 7 
delivery system, their drug content, in vivo stability and bioavailability of DTX at tumour site 8 
must all be balanced.  A phase I clinical trial (Deeken et al., 2013) was carried out in  patients 9 
with solid tumour and benefit was seen in 41 % of cases, using liposomal DTX consisting of 10 
DOPC:Chol :TMCL (90:5:5 % molar ratio) with an overall lipid:drug ratio of 33:1. Despite the 11 
known beneficial effects of PEG2000 to increase stability and prolong liposomes blood residency 12 
(Harashima et al., 1994; Johnstone et al., 2001; Yuan et al., 1995), it was not included in the 13 
formulation used in this clinical trial. Several studies showed that DTX encapsulation into 14 
liposomes was highly affected by the composition of the lipid bilayer (Immordino et al., 2003; 15 
Manjappa et al., 2013; Muthu et al., 2011; Naik et al., 2010). In this report, we systematically 16 
evaluated the effect of liposome composition, steric stabilisation, lipid:drug molar ratios, and 17 
the purification step on the final  EE and drug loading of DTX into liposomes. Our results 18 
showed that the composition and the fluidity of the lipid bilayer had a strong influence on DTX 19 
encapsulation. Prior purification, fluid-lipid bilayer liposomes (DOPC:Chol) presented the 20 
highest EE across all lipid:drug ratios assessed (Figure 1a). Almost 100 % EE was achieved 21 
between 40:1 to 10:1 lipid:DTX molar ratios, however, lowering lipid:DTX molar ratio to 5:1 22 
resulted in a lower EE (46 %). To correct for the incomplete DTX incorporation, drug loading 23 
was also calculated for all liposome formulations (Figure 1b). Interestingly, on contrary to the 24 
18 
 
EE results, DOPC-based liposomes showed the highest DTX loading at 5:1 lipid:DTX molar ratio, 1 
where 9.7 mol% DTX/total lipid was obtained, in comparison to 2.5-4 mol% DTX/total lipid at 2 
high ratios (40:1 and 20:1). Therefore, our results emphasise the importance of using drug 3 
loading, as more realistic and accurate measure of the effective drug dose entrapped in the 4 
liposomes. 5 
Lipids with high phase transition temperature (Tm) are known to have longer plasma circulation 6 
(Gabizon and Papahadjopoulos, 1988). Tm represents a characteristic temperature of lipid 7 
phase change from gel to liquid phase and it is determined by the characteristic lipid structure. 8 
DPPC (Tm = 41.85 ˚C) and DSPC (Tm = 55 ˚C) have higher Tm than DOPC (Tm = - 17 ˚C) (Attwood 9 
et al., 2013; Prates Ramalho et al., 2011). Moreover, unsaturated lipids such as DOPC are more 10 
prone to oxidation, further decreasing stability. Although stability investigation was not carried 11 
out in this study, it is expected in line with literature, that saturated lipids, such as DPPC and 12 
DSPC will be more stable compared to unsaturated liposomal compositions (Gabizon and 13 
Papahadjopoulos, 1988; Huang et al., 1998). In our study, DSPC:Chol:DSPE-PEG2000 liposomes 14 
showed the highest DTX loading (2.46 mol% DTX /total lipid) at 20:1 lipid:drug ratio. This high 15 
loading was not maintained on increasing DTX concentrations in the liposome formulation 16 
(Figure 1b). The same trend was seen with DPPC liposomes, however the best formulation, 17 
40:1, gave lower loading (0.91 ± 0.03 mol% DTX/total lipid) than any of the other lipid 18 
composition at the same lipid:drug ratio. Other studies reported higher extent of drug 19 
incorporation in DSPC liposomes as opposed to DPPC formulation (Anderson and Omri, 2004; 20 
Haeri et al., 2014). It was explained by the higher tendency of DPPC to form an interdigitated 21 
state during extrusion in comparison to DSPC, which decreases the space between the acyl 22 
chains, and therefore leads to increased DTX loss during extrusion and purification steps 23 
(Demetzos, 2008). DTX loading trend of both DPPC and DSPC formulations differed significantly 24 
compared to DOPC:Chol:DSPE-PEG2000. Unlike the downward trend experienced with 25 
decreasing lipid:drug ratio, PEGylated DOPC formulations showed an increasing drug loading 26 
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ratios tested (Figure 1b ). This may be due to differences in the structure of these lipids which 1 
affect their drug accommodation behaviour at different DTX concentration. The presence of 2 
higher drug content in the rigid bilayers could lead to DTX precipitation in the bilayer and drug 3 
loss (Johnston et al., 2006). This result agrees with the  literature, where a high lipid content 4 
(ca. 35:1) was required to maximise DTX loading into DSPC or DPPC liposomal formulations 5 
(Crosasso et al., 2000; Manjappa et al., 2013). To improve DTX encapsulation into rigid 6 
liposomes, a mix of DPPC and DSPC lipids could be used (Manjappa et al., 2013; Zhigaltsev et 7 
al., 2010). Furthermore, the cholesterol content may need to be lowered, as both molecules 8 
occupy the same region in the lipid bilayer (Lian and Ho, 2001; Zhang et al., 2005). 9 
With respect to size distribution, all liposomes formulations maintained their homogeneity 10 
irrespective of varying lipid:drug ratio (Tables 1-4), with relatively smaller sizes with PEGylated 11 
liposomes. Interestingly, DTX-loaded liposomes resulted in a smaller size than empty 12 
liposomes. The differences in liposomal size are not significant throughout lipid:drug ratios 13 
40:1, 20:1 and 10:1. Only lipid:drug ratio 5:1 presented lower size and this was consistent 14 
independently of the lipid composition used. Although further studies would be required to 15 
evaluate how this would affect the stability and drug release, we hypothesize that at the lower 16 
lipid:drug ratio the presence of DTX within the liposome bilayer is increasing the packing of the 17 
phospholipids (specially the more fluid ones composed of DOPC). A higher packing would allow 18 
increased curvature and therefore smaller size. 19 
Complete removal of free drug is a prerequisite for accurate drug dosing. Due to the wide 20 
range of techniques used to separate unencapsulated drugs, EE largely vary between studies 21 
(Lane et al., 2015). Ultracentrifugation and dialysis are the main techniques that are used to 22 
remove unentrapped DTX from liposomal samples (Grabielle-Madelmont et al., 2003; 23 
Mozafari, 2010). There are many limitations to use ultracentrifugation to purify free drug from 24 
small liposomes, since small drug-loaded liposomes could be lost in the supernatant (Grabielle-25 
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Madelmont et al., 2003; Meers Paul, 2011). Equally, drug adsorbed to the exterior of the 1 
liposomes might sediment along with the liposomes, resulting in an overestimation of the EE. 2 
Therefore, it is crucial to accurately quantify the amount of liposome-entrapped drug before 3 
studying its activity in vitro and in vivo behaviours. In the present work, SEC was the chosen for 4 
liposome purification as it is a well-established approach to separate hydrophobic liposome-5 
entrapped drugs. Unexpectedly, huge drug loss (up to 60 %) was observed following 6 
purification (Figure 1c), which was not associated with lipid loss, as shown by the high lipid 7 
recovery (90-100 %) (Table A.5). This interesting result could be explained by the assumption 8 
that large amount of the drug was not fully incorporated within the lipid bilayer, and was 9 
rather weakly bound or adsorbed to the liposome surface. Prior purification, our EE was (92-10 
100 %) which agrees with other studies where purification step was not introduced (Zhang et 11 
al., 2012). However, the EE of our purified liposomes is still much lower than DTX-liposomes 12 
purified using ultracentrifugation and dialysis (Immordino et al., 2003; Li et al., 2011; Muthu et 13 
al., 2011; Ren et al., 2016; Zhai et al., 2010).  Our findings, demonstrated the importance of 14 
using a robust and reliable method to purify DTX-loaded liposomes, since injecting non-15 
purified DTX-liposomes could lead to a substantial loss of DTX from the liposomes surface, 16 
leading to lower concentrations of DTX reaching to tumour tissues, which translates clinically 17 
into a lower therapeutic efficacy.  18 
Purification step is not only necessary for accurate dosing but also to predict the toxicity of the 19 
DXT-loaded liposomes in vitro and in vivo. Interestingly, our results showed that while using 20 
the same concentrations of DTX, non-purified DOPC:Chol liposomes were more more cytotoxic 21 
than the purified ones at early time point (24 h), however, this effect was reversed at 48-72 h 22 
(Figure 2). These results support the hypothesis of the adsorbed drug to the liposome surface 23 
which exhibits a “free drug-like behaviour” at early time points, increasing the cytotoxicity in 24 
comparison to the encapsulated drug. The burst release of adsorbed drug from the 25 
nanoparticles surface was previously reported (B. Magenheim, 1993). Longer time points (48-26 
21 
 
72 h) ensured sufficient time for DTX-loaded liposomes to be taken up and released DTX 1 
intracellularly, leading to a higher cell death. In addition to cell monolayers, and for the first 2 
time, our DTX-loaded liposomes, both conventional and sterically stabilised liposomes 3 
significantly enhanced the therapeutic efficacy of DTX in prostate cancer PC3 tumour 4 
spheroids, most likely due to the improved DTX solubility, diffusion and penetration into the 5 
inner layers of the spheroids (Chambers et al., 2014; Xu et al., 2014). 6 
4. Conclusions 7 
Our results demonstrated the effect of the lipid bilayer composition on DTX encapsulation. 8 
Liposomes composed of fluid, unsaturated DOPC lipid showed the highest DTX loading 9 
compared to rigid saturated DPPC and DSPC lipids. Steric stabilisation had minimum effect on 10 
DTX encapsulation into liposomes. Decreasing lipid:drug molar ratio from 40:1 to 5:1 led to an 11 
improvement in the loading capacities of DOPC-based liposomes only.  Our study showed, and 12 
for the first time, that SEC is a reliable method to remove adsorbed DTX to the liposome 13 
surface, resulting in an accurate drug quantification. In vitro toxicity of non-purified and 14 
purified DTX-loaded DOPC-based liposomes further confirmed the relevance of using a robust 15 
and reliable means of liposome purification, which strongly impacts the DTX dose to be 16 
delivered to the tumour cells, and therefore DTX therapeutic efficacy. Finally, an improvement 17 
in DTX solubility and penetration was observed with DTX-loaded liposomes which translated in 18 
a dose- and time-dependent cell death in PC3 prostate tumour spheroids, in contrast to the 19 
limited efficacy of free DTX. Overall, our findings shed the light on the importance of selecting 20 
the right lipid composition and method of liposome purification when engineering a liposomal 21 
nanoformulation for DTX drug. Such parameters will impact the liposome drug entrapment 22 
ability and stability and, more importantly, will dictate the therapeutic efficacy and ultimately 23 
the success of DTX-loaded liposomal formulations in vivo. 24 
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Table 1. Physicochemical properties of DTX-loaded DOPC:Chol (100:50) liposomes prepared 1 
at different lipid:DTX molar ratios. The hydrodynamic size, polydispersity index (PdI) and zeta 2 
potential (ZP) of liposomes before and after purification were measured by the Nanosizer ZS 3 
(Malvern, UK). 4 
 5 
  Before Purification After Purification 
Lipid 
composition 
(molar ratio) 
Lipid:DTX  
molar ratio 
Size ± SD 
(d.nm) 
§ n
 
PdI ± SD 
§± 
 Size ± SD 
(d.nm) 
§ n
 
PdI ± SD 
§± 
 ZP ± SD 
(mV ) 
§V 
 
 
 
 
DOPC:Chol 
(100:50) 
no drug 156.4 ± 5.0 0.118 ± 0.04 160.9±60.9 0.147 ± 0.02 -5.6 ± 0.4  
40:1 157.9 ± 1.1 0.193 ± 0.01 145.1 ± 2.8 0.210 ± 0.03 -5.4 ± 0.6 
20:1 162.0 ± 1.6  0.202 ± 0.01 136.4 ± 7.0  0.224 ± 0.01 -8.7 ± 0.7 
10:1 145.1 ± 1.9  0.170 ± 0.02 140.8 ± 0.4 0.137 ± 0.01 -2.8 ± 0.4  
5:1 129.3 ± 0.3  0.093 ± 0.01 122.2 ± 1.6 0.088 ± 0.03 -3.8 ± 0.6 
 6 
§ Data shown as mean ± SD (n = 3); † measured by dynamic light scattering; ‡ electrophoretic 7 
mobility. 8 
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Table 2. Physicochemical properties of DTX-loaded DOPC:Chol:DSPE-PEG2000 (95:50:5) 1 
liposomes prepared at different lipid:DTX molar ratios. The hydrodynamic size, polydispersity 2 
index (PdI) and zeta potential (ZP) of liposomes before and after purification were measured 3 
by the Nanosizer ZS (Malvern, UK). 4 
 5 
  Before Purification After Purification 
Lipid composition 
(molar ratio) 
Lipid:DTX  
molar 
ratio 
Size ± SD 
(d.nm) 
§ n
 
PdI ± SD 
§± 
 Size ± SD 
(d.nm) 
§ n
 
PdI ± SD 
§± 
 ZP ± SD 
(mV ) 
§V 
 
 
 
DOPC:Chol:DSPE-
PEG
2000
 
(95:50:5) 
no drug 132.3 ± 1.0 0.087 ± 0.04 142.6±42.6 0.157 ± 0.06  -11.0± 0.73 
40:1  126.7 ± 1.4 0.040 ± 0.02 133.1 ± 1.0 0.104 ± 0.01 -9.9 ± 1.5 
20:1  124.2 ± 1.8  0.030 ± 0.01 125.0 ± 4.1 0.051 ± 0.02 -9.7 ± 0.5 
10:1  117.8 ± 1.0  0.040 ± 0.00 127.4 ± 3.0  0.111 ± 0.03 -9.2 ± 0.5 
5:1  112.3 ± 2.4  0.086 ± 0.01 116.9 ± 2.4  0.131 ± 0.02 -9.4 ± 0.4 
 6 
§ Data shown as mean ± SD (n = 3); † measured by dynamic light scattering; ‡ electrophoretic 7 
mobility.  8 
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 1 
 2 
Table 3. Physicochemical properties of DTX-loaded DPPC:Chol:DSPE-PEG2000 (95:50:5) 3 
liposomes prepared at different lipid:DTX molar ratios. The hydrodynamic size, polydispersity 4 
index (PdI) and zeta potential (ZP) of liposomes before and after purification were measured 5 
by the Nanosizer ZS (Malvern, UK). 6 
 7 
  Before Purification After Purification 
Lipid 
composition 
(molar ratio) 
Lipid:DTX  
molar 
ratio 
Size ± SD 
(d.nm) 
§,†
 
PdI ± SD 
§,†
  Size ± SD 
(d.nm) 
§,†
 
PdI ± SD 
§,†
 ZP ± SD 
 (mV ) 
§,‡
 
 
DPPC:Chol:DSPE-
PEG
2000
 
(95:50:5) 
no drug 158.5 ± 6.2 0.153 ± 0.03 145.1 ± 5.1 0.088 ± 0.02 -9.69 ± 7.4 
40:1 145.5 ± 0.9 0.147 ± 0.01 136.3 ± 0.6 0.047 ± 0.02 -12.6 ± 0.6 
20:1 134.2 ± 2.0 0.131 ± 0.02 127.3 ± 0.8  0.033 ± 0.01 -7.7 ± 0.5 
10:1 133.9 ± 3.3 0.115 ± 0.06 132.9 ± 1.6  0.057 ± 0.01 -9.8 ± 0.9 
5:1 118.4 ± 4.4 0.042 ± 0.02 115.1 ± 1.8  0.072 ± 0.02 -10.3 ± 1.1 
 8 
§ Data shown as mean ± SD (n = 3); † measured by dynamic light scattering; ‡ electrophoretic 9 
mobility.  10 
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Table 4. Physicochemical properties of DTX-loaded DSPC:Chol:DSPE-PEG2000 (95:50:5) 1 
liposomes prepared at different lipid:DTX molar ratios. The hydrodynamic size, polydispersity 2 
index (PdI) and zeta potential (ZP) of liposomes before and after purification were measured 3 
by the Nanosizer ZS (Malvern, UK). 4 
 5 
  Before Purification After Purification 
Lipid 
composition 
(molar ratio) 
Lipid:DTX 
molar 
ratio 
Size ± SD 
(d.nm) 
§,†
  
PdI ± SD 
§,†
 Size ± SD 
(d.nm) 
§,†
 
PdI ± SD 
§,†
 ZP ± SD (mV 
) 
§,‡
 
 
DSPC:Chol:DSPE-
PEG
2000
 
(95:50:5) 
no drug 152.1 ± 3.7 0.069 ± 0.00 155.4 ± 3.2 0.073 ± 0.02 -9.25 ± 0.79 
40:1 132.9 ± 2.7 0.040 ± 0.02 133.0 ± 0.2 0.049 ± 0.02 -8.8 ± 0.3 
20:1 123.5 ± 2.3  0.021 ± 0.00 136.4 ± 3.6 0.094 ± 0.00 -9.5 ± 0.8 
10:1 125.7 ± 2.6  0.047 ± 0.02 131.0 ± 3.3 0.092 ± 0.01 -14.9 ± 1.0 
5:1 124.3 ± 2.2 0.067 ± 0.01 125.6 ± 0.9 0.063 ± 0.01 -12.9 ± 1.1 
 6 
§ Data shown as mean ± SD (n = 3); † measured by dynamic light scattering; ‡ electrophoretic 7 
mobility.  8 
 9 
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Figure captions: 1 
Figure 1. Encapsulation efficiency and drug loading of DTX into liposomes with different lipid 2 
compositions. DOPC:Chol, DOPC:Chol:DSPE-PEG2000, DPPC:Chol:DSPE-PEG2000 and 3 
DSPC:Chol:DSPE-PEG2000 liposomes were loaded with DTX at 40:1, 20:1, 10:1 and 5:1 4 
lipid:drug molar ratios then purified using PD-10 column. (a) Encapsulation efficiency of DTX 5 
into liposomes before purification, as determined by HPLC; DTX loading efficiency in liposomes 6 
(b) before purification and (c) after purification. Liposomes were disrupted in 10:1 (v/v) 7 
MeOH:HBS, sonicated for 10 min and DTX content was quantified by HPLC. Lipid content was 8 
determined by Stewart’s assay. Data shown as mean ± SEM (n = 3). Statistical analysis was 9 
performed using two-way ANOVA followed by Bonferroni post-test (*** p < 0.001; ** p < 0.01; 10 
* p < 0.05). Statistical analysis was performed using 20:1 lipid:DTX molar ratio of each 11 
formulation as a reference as this ratio is referred in the literature as the optimized ratio. 12 
Figure 2. Cell viability of DTX-loaded, DOPC:Chol and DOPC:Chol:DSPE-PEG2000 liposomes in 13 
PC3 cell monolayer. DTX-loaded liposomes were prepared at 20:1 molar ratio. Cells were 14 
seeded in 96-well plates (1x104 cells/well) and next day incubated in serum-free media with 1-15 
1000 nM of DTX-loaded, non-purified DOPC:Chol liposomes (black solid circles) and purified 16 
liposomes (black open circles), and with DTX-loaded, non-purified DOPC:Chol:DSPE-PEG2000 17 
liposomes (grey solid triangles) and purified liposomes (grey open triangles). After 4 h 18 
incubation, liposome-containing media were removed and cells were replenished with 19 
complete media. Cell viability was assessed by resazurin assay at (a) 24 h; (b) 48 h; (c) 72 h 20 
post-incubation. IC50 and Imax  results were summarized below each graph. Data shown as 21 
mean ± SEM (n = 6). Significance of IC50/Imax between non-purified and purified DOPC:Chol (
a< 22 
0.001) and between non-purified and purified DOPC:Chol:DSPE-PEG2000 liposomes (
b< 0.001) 23 
was performed using two-way ANOVA followed by Bonferroni post-test.  Abbreviations: IC50, 24 
half maximal inhibitory concentration; % Imax, maximum inhibition (lower cell viability). 25 
Figure 3. Cell viability of DTX-loaded, DOPC:Chol and DOPC:Chol:DSPE-PEG2000 liposomes in 26 
PC3 multicellualr tumor spheroids. Purified DTX-loaded liposomes were prepared at 20:1 27 
molar ratio. Cells were seeded in 1 % (w/v) agarose coated 96-well plates (5x103 cells/well) and 28 
after 7 days of growth spheroids were incubated in complete media with (a) free DTX (1-10000 29 
nM); (b) DTX-loaded DOPC:Chol liposomes (1-1000 nM of DTX) or (c) DTX-loaded 30 
DOPC:Chol:DSPE-PEG2000 liposomes (1-1000 nM of DTX). Cell viability was assessed by resazurin 31 
assay after 48 (black bars), 72 (grey bars) and 96 h (white bars). Data shown as mean ± SEM (n 32 
= 6). Statistical analysis was performed using two-way ANOVA followed by Bonferroni post-33 
test. * denotes comparison between 48 and 72 h, $ denotes comparison between 72 and 96 h 34 
(***, $$$ p < 0.001; ** p < 0.01; * p < 0.05). 35 
 36 
 37 
 38 
 39 
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